Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Jeffrey W. Clark, MD
- Target Recruit Count
- 35
- Registration Number
- NCT00593060
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT00591149
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 6
- Registration Number
- NCT00580073
- Locations
- 🇺🇸
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00577109
Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2007-11-20
- Lead Sponsor
- Grupo Portugues de Estudo do Cancro do Pulmao
- Target Recruit Count
- 47
- Registration Number
- NCT00561054
- Locations
- 🇵🇹
fERNANDO bARATA, cOIMBRA, Portugal
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-31
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 22
- Registration Number
- NCT00551759
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Hematology and Oncology Associates, Chicago, Illinois, United States
🇺🇸Southwest Medical Center, Liberal, Kansas, United States
Bevacizumab in Multiple Phase I Combinations
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 343
- Registration Number
- NCT00543504
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT00540943
- Locations
- 🇫🇷
GSK Investigational Site, Toulouse, France
Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 9
- Registration Number
- NCT00537823
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Pre-op Rectal ChemoRad +/- Cetuximab
- Conditions
- Interventions
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 139
- Registration Number
- NCT00527111
- Locations
- 🇺🇸
Yakima Valley Mem Hosp/North Star Lodge, Yakima, Washington, United States
🇺🇸Advanced Medical Specialties, Miami, Florida, United States
🇺🇸Melbourne Internal Medicine Associates, Melbourne, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.